Dear Editor:

Disseminated superficial actinic porokeratosis (DSAP) is distinguishable among the porokeratosis by large numbers of lesions on sun-exposed skin, and sparing of the palms and soles. The tendency to develop DSAP is inherited as an autosomal dominant characteristic. However, a certain amount of accumulated sun exposure and other factors such as immunosuppression, hepatitis, and rarely phototherapy can enhance this tendency[@B1].

A 52-year-old Korean woman had had vitiligo on her forehead, anterior chest, and abdomen for 5 years. There were no other skin lesions except for vitiligo when the patient visited our clinic, but her son has DSAP on the face. The patient was treated with topical application of corticosteroids, tacrolimus, and narrowband ultraviolet B (NB-UVB, Waldmann UV 5040KL; Waldmann, Villingen-Schwenningen, Germany) phototherapy. Several asymptomatic annular brown colored macules with thread-like borders were identified on her whole body after 7 months of irradiation ([Fig. 1A, B](#F1){ref-type="fig"}). The total cumulative irradiation dose of NB-UVB was 42.9 J/cm^2^ at that time, and she had noticed these skin lesions 2 to 3 weeks previously. Interestingly, any skin lesions did not appear in the vitiliginous areas, even though over 100 DSAP lesions had developed on the whole body. A biopsy specimen disclosed the characteristic histopathological findings of DSAP ([Fig. 1C](#F1){ref-type="fig"}).

Although we had warned patient about the risk of malignant change, the patient wanted to continue treatment. Therefore, the normal skin without vitiligo lesions was covered with the cloth during phototherapy. A few new lesions occurred within a few months of the initial detection of DSAP, and the color of lesions was getting darker with time. But the number and size of DSAP lesions were not altered until now.

Nine cases of DSAP associated with photo(chemo)therapy were reviewed ([Table 1](#T1){ref-type="table"})[@B1][@B2][@B3]. In this case, it is thought that DSAP lesions on the trunk was induced by NB-UVB because trunk is generally unexposed area to natural sunlight, and DSAP lesions developed after NB-UVB exposure. Kawara et al.[@B1] reported that DSAP was present after a total dose of 37.8 J/cm^2^ for 33 months. In our case, DSAP lesions were found at a 42.9 J/cm^2^ in total cumulative dose after 7 months\' NB-UVB therapy.

The pathogenesis of DSAP after phototherapy is uncertain. NB-UVB therapy promotes the release of keratinocytic growth factors and is also known to suppress the immune system and reduce inflammation by modulating cytokine patterns, irradiating T cells, and inducing apoptosis[@B4]. It is possible that chronic immunosuppressive conditions under long-term NB-UVB phototherapy induce clonal proliferation of abnormal keratinocytes.

Though it may be a coincidental finding, the very interesting point in this case is that DSAP lesions did not develop on the areas with vitiligo lesions. So it is thought that the occurrence of DSAP was prevented by vitiligo. Although the underlying mechanism is unknown, it is supposed that this is a similar reason as in vitiligo lesions does not increase the risk of sun induced skin cancer[@B5]. Therefore, further studies and accumulation of case reports are needed to reveal the relationship between vitiligo and DSAP, as well as the underlying mechanisms for DSAP development.
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![Clinical and histopathological findings and punch biopsy specimen from disseminated superficial actinic porokeratosis on the abdomen. (A\~C) Small round hyperpigmented macules with a keratotic, thread border on her face and abdomen. Histopathological findings show a shallow, keratin-filled invagination. Cornoid lamella with irregularly arranged keratinocytes in the spinous layer (C: H&E, ×400).](ad-30-249-g001){#F1}

###### Summary of photo(chemo)therapy-induced disseminated superficial actinic porokeratosis reported in the literatures

![](ad-30-249-i001)

  Authors (year)              Sex/age (yr)   Skin disease   Phototherapy   Duration   Total irradiance (J/cm^2^)   Site
  --------------------------- -------------- -------------- -------------- ---------- ---------------------------- -----------------------------------
  Reymond et al. (1980)       F/67           Psoriasis      Oral PUVA      24 mo      961                          Legs
  Farber et al. (1982)        M/66           Psoriasis      Oral PUVA      12 mo      280                          Lower limbs, arms, chest, back
  F/45                        Psoriasis      Oral PUVA      36 mo          4,173      Limbs                        
  Hazen et al. (1985)         F/30           Psoriasis      Oral PUVA      1.5 mo     19.5                         Legs
  Cockerell (1991)            M/60           Psoriasis      BBUVB          13 d       0.44                         Trunk, legs, arms
  Lee et al.[@B2] (1992)      F/20           Vitiligo       Topical PUVA   Unknown    0.4                          Anterior chest
  Allen et al. (2000)         F/54           Psoriasis      Topical PUVA   2.5 mo     49.8                         Heels, ankles (PUVA-treated area)
  Kawara et al.[@B1] (2011)   M/75           Psoriasis      NB-UVB         33 mo      37.8                         Trunk
  Present case                F/52           Vitiligo       NB-UVB         7 mo       42.9                         Face, anterior chest, abdomen

F: female, M: male, PUVA: psoralen and ultraviolet A therapy, BBUVB: broadband ultraviolet B, NB-UVB: narrowband ultraviolet B.
